3[3]Fox RI. Mechanism of action of leflunomide in RA[J].J Rheum .1998,25(Suppl 53)∶S27-S32．
4[4]Smolen JS,Kalden JR,Scott DL，et al.Efficacy and safety of le flunomid e compared with placebo and sulphasalazine in active RA:a double-blind, randomi zed,multicenter trial[J].Lancet,1999,353,9149∶259-266．
5[5]Rozman B.Clinical experience with leflunomide in RA[J].J Rheu m，1998,25 (Suppl 53)∶S20-S26．
6[6]Weaver A,Caldwell J,Olsen N,et al.Treatment of active RA with lefluno mide compared to placebo or MTX[C].Poster at 62nd ACR in San Diego, 1998.
7[7]Moldovan F,Pelletier JP,Jolicoeur FC,et al.Diacerhein and rhe in redu ce the ICE induced IL-1β and IL-18 activation in human osteoarthritic cartila ge[J].Osteoarthritis and Cartilage，2000,8(3)∶186-196.
8[8]Moreland LW,Baunmgartner SW,Schiff MH,et al.Treatment of RA w ith a re combinant human tumor necrosis receptor (P75)-Fc fusion protein[J].New Eng J Med，1997，337∶141-147．
9[9]Weinblatt ME,Kremer JM,Bankhurst AD,et al.A trial of Etanerc ept,a re combinant tumor necrosis factor receptor: Fc fusion protein, in patients with RA receiving MTX[J].New Eng J Med，1999,340(4)∶253-259．
10[10]Mani RN,Breedveld FC,Kalden JR,et al.Therapeutic efficacy of multipl e intravenous infusion of anti-tumor necrosis factor a monoclone antibody compa red with low dose weekly MTX in RA[J].Arthritis Rheum，1998,41(9)∶1552-15 63.
